BRCA1 and BRCA2 Hereditary Gene Analysis Deletion and Duplication

Abbrev Code:BRCO12   
Order Code:LAB6949Order Name:Hereditary Cancer BRCA1/BRCA2
Synonyms:Comprehensive BRAC Analysis; NGS; Genetic Testing; Hereditary Breast and Ovarian Cancer Syndrome; HBOC; Breast Cancer; Hereditary Breast Cancer; Early Onset Breast Cancer; Ovarian Cancer; BRCA1; BRCA2; Familial Cancer; BRCA1/BRCA2; Hereditary
Methodology:Next generation sequencing
CPT Codes: 81162 x1
Turnaround Time:Testing is performed Mon-Fri; results are reported within 4-6 weeks.
Special Instructions:Gene(s) or the name of the panel should be indicated in the comment section of EPIC order.
A signed informed consent in the patient's medical record is required; the consent should not be sent to the laboratory. The link to the Genetic Testing Consent Form is provided as a convenience for the providers and genetic counselors. Bone Marrow Transplant patients: If a patient is the recipient of an allogeneic transplant, this test must be done on a pre-transplant sample. Contact the Molecular Diagnostics lab to see if a pre-transplant sample is available.
Associated Links:

Genetic Testing Consent Form

Collection Instructions

Optimal Volume:10 mL
Minimum\Peds Volume:3 mL
Container:Yellow (ACD, Solution A) tube available from laboratory
Alternate Containers: Purple (EDTA)
Causes for Rejection:Frozen or clotted specimen, incorrect anticoagulant, specimen more than 5 days old. Sample collected from bone marrow transplant recipient. Samples tested in hematology using automated instrumentation not accepted. DNA extracted at non-CLIA certified (or equivalent) lab.

Processing and Shipping

Specimen Processing:Do not process. Store at room temperature.
Shipping Instructions:Ship at room temperature.
Stability:5 days at room temperature.
Test Performed at or Referral Lab Molecular Diagnostics  (UMMC East Bank)


Reference Range:By report
Use:The BRCA 1 / 2 cancer  panel analyzes two genes associated with the Hereditary Breast and Ovarian Cancer Syndrome (HBOC) which increases the lifetime risk of breast and ovarian cancer, and other cancers. Published medical guidelines exist for detection, prevention, risk reduction and/or treatment.This assay utilizes a next generation sequencing (NGS) platform. This platform allows simultaneous sequencing of a large number of genes using a single assay. Genomic DNA is extracted from the sample, and the sequencing libraries are prepared according to standard Illumina protocols using the TruSight One Sequencing Panel for enrichment of targeted genes. The enriched DNA libraries are sequenced on an Ilumina HiSeq 2500 instrument. Raw sequencing reads are mapped to the reference genome using BWA. Raw alignment files are realigned in the neighborhood of indels, and recalibrated for base quality accuracy using the Genome Analysis Tool Kit (GATK) Point mutation and indel calls in exons and adjoining intronic regions are made using the GATK Unified Genotyper. Variants are interpreted according to guidance issued by the American College of Medical Genetics.

Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact: for TestID: 3853"